Response by Figtree et al to Letter Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)".
暂无分享,去创建一个
[1] S. Solomon,et al. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus , 2018, Circulation.
[2] Yoshinobu Morikawa,et al. The diabetic heart utilizes ketone bodies as an energy source. , 2017, Metabolism: clinical and experimental.
[3] A. Quyyumi,et al. The Prognostic Significance of Diabetes and Microvascular Complications in Patients With Heart Failure With Preserved Ejection Fraction , 2017, Diabetes Care.
[4] C. Lang,et al. Renal and Cardiovascular Effects of sodium–glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial , 2017, BMJ Open.
[5] J. Adamski,et al. Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease. , 2017, Circulation.
[6] Sanjiv J. Shah,et al. The potential role and rationale for treatment of heart failure with sodium–glucose co‐transporter 2 inhibitors , 2017, European journal of heart failure.
[7] B. Staels. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. , 2017, The American journal of cardiology.
[8] K. Mahaffey,et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.
[9] K. Mahaffey,et al. Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials , 2017, Diabetes, obesity & metabolism.
[10] F. Gueyffier,et al. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials. , 2017, Diabetes & metabolism.
[11] D. Fitchett,et al. Heart failure outcomes in clinical trials of glucose‐lowering agents in patients with diabetes , 2017, European journal of heart failure.
[12] H. Bøtker,et al. Heart failure patients with prediabetes and newly diagnosed diabetes display abnormalities in myocardial metabolism , 2018, Journal of Nuclear Cardiology.
[13] D. Fitchett,et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. , 2016, Circulation.
[14] Rick B. Vega,et al. The Failing Heart Relies on Ketone Bodies as a Fuel , 2016, Circulation.
[15] T. Pieber,et al. Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes , 2016, Diabetes.
[16] B. Zinman,et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial , 2016, European heart journal.
[17] B. Zinman,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.
[18] Amit X Garg,et al. Worldwide access to treatment for end-stage kidney disease: a systematic review , 2015, The Lancet.
[19] Spiros Denaxas,et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people , 2015, The Lancet.
[20] M. Monami,et al. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. , 2014, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[21] C. O'connor,et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. , 2014, European heart journal.
[22] Stephen B Wheatcroft,et al. Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology , 2013, Diabetes & vascular disease research.
[23] Arshed A Quyyumi,et al. Endothelial dysfunction, arterial stiffness, and heart failure. , 2012, Journal of the American College of Cardiology.
[24] D. Loo,et al. Biology of human sodium glucose transporters. , 2011, Physiological reviews.
[25] J. Shaw,et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. , 2011, Diabetes research and clinical practice.
[26] Thomas Lumley,et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. , 2003, JAMA.
[27] P. McNulty,et al. Diabetes mellitus and heart failure. , 2003, Congestive heart failure.
[28] D G Altman,et al. Calculating the number needed to treat for trials where the outcome is time to an event , 1999, BMJ.
[29] P. Allhoff,et al. Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle Aged Men with Dyslipidemia , 1991 .
[30] E. Ogata,et al. Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. , 1990, The New England journal of medicine.
[31] K. Carlström,et al. TREATMENT OF CLIMACTERIC AND POSTMENOPAUSAL WOMEN WITH 17‐β‐OESTRADIOL AND NORETHISTERONE ACETATE , 1977, Acta obstetricia et gynecologica Scandinavica.